A Phase 2 interventional study of L-Citrulline and Placebo in Acute Hypoxemic Respiratory Failure, sponsored by Asklepion Pharmaceuticals, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-22.
Sponsored by Asklepion Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.
Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 96th largest by enrollment of the 253 interventional ones that give a count, is one of 42 that started in 2020, is one of 28 in phase 2, and was the 254th registered.
1,370 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.
Browse Respiratory Insufficiency studies →44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages up to 28 days
University of Rochester · Sites in United States
Ages 18+ · Healthy volunteers
Thomas Jefferson University · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 42 · Phase 3 27 · Phase 4 9
First in 1992; this study’s year is marked. 42 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 42 across the 253 interventional studies, 65 across the 95 observational. Of the 246 that completed or were terminated, 93 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 349 have an industry lead sponsor. The 10 most frequent:
Asklepion Pharmaceuticals, LLC is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Asklepion Pharmaceuticals, LLC has 1 study filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
24 of the studies in Respiratory Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217197Thomas Jefferson UniversityRespiratory Monitoring System That Detects & Predicts OIRD | 2026-11-30 |
| NCT04664192Baylor Research InstituteBio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research | 2026-12-01 |
| NCT05462600University of California, San DiegoDistribution of Ventilation, Respiratory Drive and Gas Exchange: Measurements and Monitoring | 2026-12-30 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT06938217Institute for Extracorporeal Life SupportSafety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 349 studies in Respiratory Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients with COVID-19 (SARS-CoV2) Illness. To evaluate safety and efficacy of a bolus loading dose and continuous intravenous infusion of L-Citrulline compared to placebo in patients hospitalized with COVID-19 infection (SARS-CoV-2).
Intravenous L-citrulline (Turnobi) administration will safely restore the homeostasis of nitric oxide synthase by increasing both plasma citrulline and arginine levels. Investigators also reason that restoration of citrulline/arginine balance through citrulline administration will safely re-establish homeostasis of NOS, lower oxidative stress, and reduce inflammation, thereby delaying and potentially preventing the need for invasive mechanical ventilation in participants hospitalized with COVID-19 infection (SARS-CoV-2). The body lives in a delicate balance of homeostasis. The urea/NO cycle plays a critical role in maintaining redox homeostasis and as such, also plays a role in regulating inflammation. The biochemical relationships are complex and depend on inter-organ transfer, membrane transport, and intracellular compartmentation. However, data above demonstrate that citrulline, arginine, and NO are critical in maintaining this homeostasis through their regulation of NOS. Inflammation, especially from infection, results in decreased activity of CPS1 and increased activity of arginase, which decreases levels of both citrulline and arginine. These decreased levels result in dysregulated and uncoupled NOS, which drives both overexuberant NO production and formation of ROS. Both the NO production and ROS further exacerbate the inflammatory cascade, resulting in other organ dysfunctions, including acute lung injury. Both inflammation and oxidative stress have been shown to be driving forces for the development of ALI and regulated NOS function is vital to reducing both. Both plasma citrulline and arginine are deficient in sepsis and levels are inversely associated with development of ALI. Furthermore, citrulline replacement safely increases plasma levels of both citrulline and arginine in healthy volunteers, BMT patients, adults with sepsis, children with sickle cell disease, and children after congenital heart surgery. It seems highly likely that citrulline therapy in the setting of COVID-19 (SARS-CoV2) induced acute hypoxemic respiratory illness will safely increase citrulline and arginine levels and help re-establish NOS homeostasis, resulting in NO production in compartments that are more homeostatically appropriate so as to reduce pulmonary vascular resistance and enhance coupling of NOS to minimize superoxide production thus reducing free radical mediated ALI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
Drug: L-Citrulline
Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
Drug: Placebo
L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
Also known as: L-CIT, CIT
Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
Time to Non-invasive/Invasive Mechanical Ventilation
Time in hours from the initiation of the treatment until mechanical ventilation is required, whether non-invasive (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) or invasive (i.e., requiring intubation).
Time frame: From the start of infusion to Day 60 Follow-up
Time to Non-invasive Mechanical Ventilation
Time in hours from the initiation of the treatment until non-invasive mechanical ventilation is required (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) .
Time frame: From the start of infusion to Day 60 Follow-up
Time to Invasive Mechanical Ventilation
Time in hours from the initiation of the treatment until intubation for invasive mechanical ventilation is required.
Time frame: From the start of infusion to Day 60 Follow-up
Systolic Blood Pressure
Systolic blood pressure measured in mmHg
Time frame: Day 1
Diastolic Blood Pressure
Diastolic blood pressure measured in mmHg
Time frame: Day 1
Mean Arterial Pressure
Mean arterial pressure measured in mmHg
Time frame: Day 1
Blood Levels of Arginine
Plasma levels of arginine
Time frame: Plasma levels of arginine at 0, 2 and 12 hours, and 2, 4, 6, 8, 10 days after initiation of treatment
Blood Levels of Citrulline
Plasma levels of citrulline
Time frame: Plasma levels of citrulline at 0, 2 and 12 hours, and 2, 4, 6, 8, 10 days after initiation of treatment
Evaluate the Effect of Intravenous L-Citrulline Compared to Placebo as Measured by the Total Length of All Mechanical Ventilation
Total length of time of any mechanical ventilation
Time frame: Day 1 through Day 60 Follow Up
Evaluate the Effect of IV L-Citrulline to Placebo for Hospital All Cause Mortality
To evaluate the effect of intravenous L-Citrulline compared to placebo on Hospital all-cause mortality
Time frame: Day 1 through day 12
Percentage of Patients Admitted to Intensive Care
Time frame: Day 1 through Day 12 (DC)
Duration of Intensive Care Unit (ICU) Stay
Length of ICU stay (days)
Time frame: From admission to ICU until discharge or death
Duration of Hospitalisation
Length of hospital stay (days)
Time frame: From admission to hospital until discharge or death
Number of Patients Requiring Intubation
Percentage of patients requiring any mechanical ventilation, invasive mechanical ventilation and non-invasive mechanical ventilation.
Time frame: From the start of infusion to Day 60 Follow-up
Overall Duration of Mechanical Ventilation
Total time on any mechanical ventilation, invasive mechanical ventilation, non-invasive mechanical ventilation and nasal cannula
Time frame: From the start of infusion to Day 60 Follow-up
| Milestone | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Started | 33 | 32 |
| Completed | 22 | 23 |
| Not completed | 11 | 9 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Death | 2 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 |
Time in hours from the initiation of the treatment until mechanical ventilation is required, whether non-invasive (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) or invasive (i.e., requiring intubation).
| Hours | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Time to Non-invasive/Invasive Mechanical Ventilation | 96.65 ± 143.73 | 70.49 ± 62.44 |
Time in hours from the initiation of the treatment until non-invasive mechanical ventilation is required (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) .
| Hours | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Time to Non-invasive Mechanical Ventilation | 66.17 ± 105.40 | 105.70 ± 108.90 |
Time in hours from the initiation of the treatment until intubation for invasive mechanical ventilation is required.
| Hours | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Time to Invasive Mechanical Ventilation | 290.01 ± 254.31 | 148.07 ± 108.08 |
Systolic blood pressure measured in mmHg
| Millimeters of mercury | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Systolic Blood Pressure | 118.63 ± 14.69 | 130.19 ± 15.71 |
Diastolic blood pressure measured in mmHg
| Millimeters of mercury | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Diastolic Blood Pressure | 73.58 ± 10.06 | 79.74 ± 13.13 |
Mean arterial pressure measured in mmHg
| Millimeters of mercury | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Mean Arterial Pressure | 87.58 ± 10.03 | 94.30 ± 13.49 |
Plasma levels of arginine
| µmol/L | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Hour 0 | 67.6 ± 28.27 | 67.88 ± 29.51 |
| Hour 2 | 92.57 ± 30.84 | 71.51 ± 29.15 |
| Hour 12 | 128.11 ± 41.3 | 75.7 ± 24.54 |
| Day 2 | 142.02 ± 54.51 | 82.19 ± 26.33 |
| Day 4 | 152.00 ± 66.7 | 79.66 ± 22.84 |
| Day 6 | 169.33 ± 113.62 | 70.78 ± 19.46 |
| Day 8 | 167.64 ± 82.5 | 81.79 ± 32.28 |
| Day 10 | 160.02 ± 83.39 | 83.9 ± 37.36 |
Plasma levels of citrulline
| µmol/L | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Hour 0 | 24.64 ± 25.91 | 18.08 ± 13.7 |
| Hour 2 | 1094.41 ± 2463.97 | 18.39 ± 14.08 |
| Hour 12 | 997.61 ± 2133.07 | 21.84 ± 16.14 |
| Day 2 | 278.2 ± 353.32 | 24.68 ± 27.57 |
| Day 4 | 626.33 ± 1562.95 | 20.53 ± 15.84 |
| Day 6 | 185.14 ± 68.63 | 20.96 ± 10.16 |
| Day 8 | 192.72 ± 127.72 | 24.84 ± 9.64 |
| Day 10 | 206.26 ± 135.94 | 24.56 ± 11.46 |
Total length of time of any mechanical ventilation
| Hours | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Evaluate the Effect of Intravenous L-Citrulline Compared to Placebo as Measured by the Total Length of All Mechanical Ventilation | 270.91 ± 304.03 | 451.87 ± 503.68 |
To evaluate the effect of intravenous L-Citrulline compared to placebo on Hospital all-cause mortality
| Participants | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Evaluate the Effect of IV L-Citrulline to Placebo for Hospital All Cause Mortality | 2 | 5 |
| Participants | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Percentage of Patients Admitted to Intensive Care | 12 | 13 |
Length of ICU stay (days)
| Days | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Duration of Intensive Care Unit (ICU) Stay | 14.83 ± 12.29 | 17.31 ± 18.87 |
Length of hospital stay (days)
| Days | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Duration of Hospitalisation | 10.61 ± 12.74 | 11.88 ± 14.29 |
Percentage of patients requiring any mechanical ventilation, invasive mechanical ventilation and non-invasive mechanical ventilation.
| Participants | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Non-invasive/invasive mechanical ventilation | 14 | 12 |
| Non-invasive mechanical ventilation | 12 | 10 |
| Invasive mechanical ventilation | 4 | 6 |
Total time on any mechanical ventilation, invasive mechanical ventilation, non-invasive mechanical ventilation and nasal cannula
| Hours | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Total time on mechanical ventilation | 239.31 ± 243.08 | 222.08 ± 370.90 |
| Total time of non-invasive mechanical ventilation | 224.64 ± 254.22 | 219.27 ± 309.40 |
| Total time of invasive mechanical ventilation | 274.27 ± 158.86 | 538.28 ± 469.21 |
| Total time on Nasal Cannula | 239.31 ± 243.08 | 222.08 ± 370.90 |
Collected over Adverse events data were collected from the time that the participant was first administered the study infusion (study hour = 0) until Day 10. Adverse events spontaneously reported to the investigator or observed by the investigator after Day 10 until Day 60 Follow Up were also collected and recorded.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV L-Citrulline (Turnobi) Arm | 2/33 (6.1%) | 6/33 (18.2%) | 11/33 (33.3%) |
| Placebo Arm | 5/32 (15.6%) | 10/32 (31.3%) | 11/32 (34.4%) |
| Event | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/33 | 3/32 |
| Cardiac arrestCardiac disorders | 0/33 | 2/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/33 | 0/32 |
| Intracranial hemorrhageVascular disorders | 1/33 | 1/32 |
| Acute Respiratory Distress Syndrome, PneumoniaRespiratory, thoracic and mediastinal disorders | 0/33 | 1/32 |
| Acute kidney injury; renal tubular necrosisRenal and urinary disorders | 0/33 | 1/32 |
| Brain InjuryNervous system disorders | 0/33 | 1/32 |
| Cardiac valve vegetationCardiac disorders | 0/33 | 1/32 |
| Cardio-respiratory ArrestRespiratory, thoracic and mediastinal disorders | 0/33 | 1/32 |
| Cardiac Failure CongestiveCardiac disorders | 0/33 | 1/32 |
| Event | IV L-Citrulline (Turnobi) Arm | Placebo Arm |
|---|---|---|
| Infusion Site ReactionGeneral disorders | 3/33 | 2/32 |
| Acute kidney injuryRenal and urinary disorders | 0/33 | 2/32 |
| Clostridium Difficile InfectionInfections and infestations | 2/33 | 0/32 |
| Deep Vein ThrombosisVascular disorders | 2/33 | 1/32 |
| Urinary Tract InfectionInfections and infestations | 2/33 | 0/32 |
| Chest PainGeneral disorders | 0/33 | 1/32 |
| ConstipationGastrointestinal disorders | 0/33 | 1/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/33 | 1/32 |
| DehydrationMetabolism and nutrition disorders | 0/33 | 1/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/33 | 1/32 |
| Age, Continuous(years) | IV L-Citrulline (Turnobi) Arm | Placebo Arm | Total |
|---|---|---|---|
| Mean | 50.30 ± 11.04 | 51.13 ± 10.34 | 50.71 ± 10.63 |
| Age, Customized(Participants) | IV L-Citrulline (Turnobi) Arm | Placebo Arm | Total |
|---|---|---|---|
| 18-49 years | 13 | 12 | 25 |
| 50-65 years | 20 | 20 | 40 |
| Sex: Female, Male(Participants) | IV L-Citrulline (Turnobi) Arm | Placebo Arm | Total |
|---|---|---|---|
| Female | 16 | 9 | 25 |
| Male | 17 | 23 | 40 |
| Ethnicity (NIH/OMB)(Participants) | IV L-Citrulline (Turnobi) Arm | Placebo Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 29 | 26 | 55 |
| Unknown or Not Reported | 1 | 4 | 5 |
| Race (NIH/OMB)(Participants) | IV L-Citrulline (Turnobi) Arm | Placebo Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 18 | 17 | 35 |
| White | 12 | 12 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Aug 2021, 10 months.
Results were first posted in Feb 2023, 1 year 5 months after primary completion.
Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Citrulline
Asklepion Pharmaceuticals, LLC